BLFS: BioLife Solutions, Inc. Stock

SIC 3845 – Electromedical and Electrotherapeutic Apparatus

Valuation
Market Cap ($M) 836.24
Enterprise Value ($M) 825.98
Book Value ($M) 337.66
Book Value / Share 7.45
Price / Book 2.48
NCAV ($M) 45.55
NCAV / Share 1.01
Price / NCAV 18.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.17
Return on Assets (ROA) -0.15
Return on Equity (ROE) -0.18

Liquidity (mrq)
Quick Ratio 1.83
Current Ratio 2.86

Balance Sheet (mrq) ($M)
Current Assets 120.60
Assets 412.71
Liabilities 75.05
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 143.27
Operating Income -57.53
Net Income -66.43
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -12.50
Cash from Investing 17.84
Cash from Financing 10.59

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-13 13G/A Vanguard Group Inc 5.71 4.24
02-02 13G Goldman Sachs Group Inc 5.50
01-24 13G/A Integrated Core Strategies (us) Llc 5.40 -2.79
01-23 13G/A BlackRock Inc. 12.30 -0.97
10-24 13D/A Casdin Capital, LLC 19.50 17.03

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT PURSUANT T
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO SEC
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SE
2023-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-03-28 50,818 428,021 11.87
2024-03-27 54,695 523,936 10.44
2024-03-26 52,516 352,000 14.92
2024-03-25 61,885 271,376 22.80

(click for more detail)

Similar Companies
BIOL – BIOLASE, Inc. BJDX – Bluejay Diagnostics, Inc.
BLAC – Bellevue Life Sciences Acquisition Corp. BRSH – Bruush Oral Care Inc.
BSGM – BioSig Technologies, Inc.


Financial data and stock pages provided by
Fintel.io